Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
New deal strengthens Congenica’s presence in India
Investment in response to increased demand for North American-based chemistry services
Sridhar will continue to serve in his current position of Managing Director for as long a period as required until the identification, selection and transition to the new leadership takes place in the company.
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Subscribe To Our Newsletter & Stay Updated
